Core Insights - QuoteMedia, Inc. reported its highest quarterly revenue in company history for Q1 2025, amounting to $4,824,356, a 3% increase from $4,679,200 in Q1 2024 [3][7] - The company experienced a net loss of $499,811 in Q1 2025, compared to a net loss of $28,176 in Q1 2024, indicating a decrease in profitability [7][12] - Adjusted EBITDA for Q1 2025 was $368,269, down from $676,886 in Q1 2024, reflecting a reduction of $308,617 [7][12] Financial Performance - Quarterly revenue increased by $145,156 (3%) year-over-year, with a 5% growth on an FX-neutral basis [7][14] - The significant loss for the quarter was attributed to capitalizing a lower proportion of development costs compared to previous quarters, which increased expensed development costs [4][13] - The company expects continued growth throughout the year, aiming for its highest annual revenue ever [3][13] Business Overview - QuoteMedia provides a range of market data services, including streaming data feeds and financial applications, targeting banks, brokerage firms, and sophisticated investors [2][6] - The company competes with larger legacy organizations and smaller companies in the financial data sector [2] - QuoteMedia's offerings include interactive stock research tools and data feeds for major financial institutions [6]

Core Insights - KORE Group Holdings, Inc. reported solid operational performance with growth in cash flow and free cash flow, achieving positive cash flow for the second consecutive quarter [3][8] - The company is nearing a significant milestone of 20 million total IoT connections, with strong demand expected to convert into increased connectivity revenue [3][8] - KORE expanded its indirect channel to focus on profitable growth, leveraging its brand for new opportunities [4] Financial Performance - Total revenue for the quarter ended March 31, 2025, was $72.142 million, a decrease of 5% from $75.975 million in the same period last year [6] - IoT Connectivity revenue was $53.917 million, down 7% from $57.884 million, while IoT Solutions revenue increased to $18.225 million, up 1% from $18.091 million [6] - Total connections increased to 19.8 million, an 8% rise from 18.3 million year-over-year [8] Cash Flow and Expenses - Cash provided by operations rose to $2.9 million, a 51% increase from the previous year, while free cash flow reached $0.6 million, up 121% [8] - Operating expenses decreased to $41.6 million, down 15% from $49.1 million, attributed to restructuring efforts [8] Margins and Key Metrics - IoT Solutions margin improved to 33.0%, up 210 basis points from the previous year, while non-GAAP margin rose to 39.9%, an increase of 370 basis points [8] - Average Revenue Per User (ARPU) decreased to $0.91 from $1.05, and the Dollar-Based Net Expansion Rate (DBNER) improved to 99% from 94% [6][8] 2025 Financial Outlook - The company expects total revenue for the year to be in the range of $288 million to $298 million, with adjusted EBITDA projected between $62 million and $67 million, and free cash flow anticipated to be between $10 million and $14 million [9]

Core Insights - SRx Health Solutions Inc. reported a significant improvement in its financial performance for Q1 2025, with EPS improving by 90% year-over-year to $(0.37) and adjusted EBITDA loss improving by 54% to $(0.6) million [1][9] - The company generated net sales of $7.2 million, a decrease of 9% year-over-year, primarily due to the closure of Halo's direct-to-consumer channel [4][9] - The merger with SRx Health Solutions was completed on April 24, 2025, leading to a name change from Better Choice Company Inc. to SRx Health Solutions Inc. [2] Financial Performance - Adjusted EBITDA margin improved by 865 basis points year-over-year to (9)% [1][9] - Net loss improved by 66% year-over-year to $(1.0) million [9] - Gross margin remained consistent at 33% [9] Operational Highlights - The company executed a digital-first strategy and shifted marketing investments to enhance brand awareness [2] - Inventory levels improved by approximately 50% over the last 15 months, with fill rates averaging 98% for the quarter [2] - The financial results reported only reflect US operations prior to the merger and do not include Canadian operations [2] Liquidity and Capital Resources - As of March 31, 2025, cash and cash equivalents totaled $1.1 million [5]

Core Insights - Alliance Entertainment Holding Corporation reported a net income of $1.9 million for the third quarter of FY 2025, marking a $5.3 million improvement year-over-year, indicating strong operational execution and margin gains [1][11] - The company reduced its revolver debt by 25% year-over-year, enhancing its balance sheet and liquidity position [1][11] - Direct to Consumer sales accounted for 35% of gross revenue, up from 33% in the same quarter of the previous year, reflecting a growing trend in consumer fulfillment [1][10] Financial Performance - Net revenues for the third quarter ended March 31, 2025, were $213.0 million, a 1% increase from $211.2 million in the same period of 2024 [15] - Gross profit for the third quarter was $29.1 million, up 3.7% from $28.0 million year-over-year, with a gross profit margin of 13.6%, compared to 13.2% in the prior year [15] - Adjusted EBITDA for the quarter was $4.9 million, reflecting a 66% increase from $2.9 million in the same period of 2024 [11][15] Operational Highlights - The company launched a distribution partnership with Paramount Pictures, becoming the exclusive licensee of Paramount's physical media in the U.S. and Canada, which strengthens its position in the home entertainment market [6][5] - Physical movie sales surged 39% year-over-year, increasing from $42 million to $58 million, driven by new exclusive content partnerships [6] - Vinyl record sales increased by 11% year-over-year, rising from $78 million to $86 million, supported by strong consumer demand [6] Inventory and Cost Management - Inventory levels improved to $93.2 million, down 13% from $108.0 million at March 31, 2024, indicating better inventory turnover and working capital efficiency [6] - Total operating expenses decreased by 11.4% year-over-year, with distribution and fulfillment costs declining by 10.2% due to automation initiatives [6] - Interest expense declined by 20.2% year-over-year, reflecting a lower revolving credit balance and improved financial efficiency [6]

Financial Data and Key Metrics Changes - Product sales for the first quarter of 2025 increased by 11% or $810,000 to a record $8,100,000 compared to the first quarter of 2024 [9] - The twelve-month period ended 03/31/2025 saw a 28% increase in product sales, amounting to $27,300,000 compared to the previous year [10] - Adjusted EBITDA for the three, six, and twelve-month periods ended 03/31/2025 was $2,300,000, $3,700,000, and $3,300,000 respectively, showing significant improvement from the previous year [12] Business Line Data and Key Metrics Changes - The sales mix for Tri Shield constituted 71% of total sales in the latest quarter, up from 55% in the previous quarter [17] - The company is developing a new bulk powder product, expected to be launched in the latter half of 2025, which will serve as a seed additive for large ranches [20] Market Data and Key Metrics Changes - The order backlog decreased from $4,400,000 as of 12/31/2024 to $4,000,000 as of 03/31/2025, and further reduced to $3,400,000 by 05/06/2025 [9] Company Strategy and Development Direction - The company is focused on expanding its product offerings and increasing production capacity, with investments exceeding $30,000,000 to enhance production facilities [6] - Management emphasizes the importance of avoiding contamination events and maintaining strong production yields to drive cash flows [10] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the company's trajectory for the remainder of 2025, highlighting the positive sales growth and improved cash balance [6] - The company is currently in a recovery phase, with expectations for continued growth driven by increased production capacity and backlog clearance [39] Other Important Information - The company has not experienced any contamination events for over a year, which is crucial for maintaining production efficiency [6] - The introduction of investigational product use for Repayne aims to gather market feedback while minimizing product development costs [7] Q&A Session Summary Question: Inquiry about product mix and its impact on gross margin - Management confirmed that Tri Shield has been a significant driver of growth due to its broader claims and efficacy, and while the bulk powder product is still in development, it is expected to contribute positively in the future [19][20] Question: Clarification on EBITDA erosion from past contamination events - Management indicated that the last contamination event occurred in April 2024, affecting primarily the first quarter of that year, with a revenue rebound starting in the fourth quarter of 2024 [30][35] Question: Expectations for future revenue and EBITDA - Management suggested that the core business EBITDA run rate is expected to be higher than the reported figures due to improved operational conditions and backlog clearance [40][41] Question: Discussion on product development expenses and their impact on EBITDA - Management acknowledged that significant investments in product development are impacting current EBITDA but are necessary for future growth and product approvals [45][50] Question: Difference between investigational use and commercial approval - Management explained that investigational use allows for product testing and data collection without generating revenue, while awaiting full FDA approval [61][62]

Core Viewpoint - Vaso Corporation reported record first quarter revenue of $19.5 million for the three months ended March 31, 2025, marking a 3.9% increase year-over-year, with improvements in gross profit and a narrowed net loss [2][3][6]. Financial Performance - Revenue for the first quarter of 2025 was $19.5 million, up from $18.7 million in the same period of 2024, driven by increases in the IT and professional sales service segments [3]. - Gross profit increased by $440 thousand, or 4.0%, to $11.4 million compared to $10.9 million in the first quarter of 2024, attributed to higher revenues [4]. - Selling, general and administrative (SG&A) expenses rose by $332 thousand, or 2.8%, to $12.4 million, mainly due to higher personnel costs in IT and professional sales services [5]. - Operating loss for the first quarter was $1.2 million, an improvement from a loss of $1.5 million in the same quarter of 2024 [6]. - Net loss narrowed to $1.1 million from $1.2 million year-over-year [6]. - Adjusted EBITDA was negative $1.1 million, an improvement from negative $1.3 million in the first quarter of 2024 [7]. Balance Sheet and Cash Flow - As of March 31, 2025, the company had $25.3 million in cash and cash equivalents, with total deferred revenue growing to $35.4 million, a 12.7% increase from the previous year [2][8]. - Net cash used in operating activities improved to $566 thousand from $1.1 million in the first quarter of 2024 [8]. - Total current assets were $45.981 million, while total assets were $77.914 million as of March 31, 2025 [15].

Core Insights - Sylogist Ltd. reported strong Q1 2025 results, achieving record bookings and significant growth in SaaS revenue, indicating successful execution of its SaaS-focused strategy [2][3][7] Financial Performance - Total revenue for Q1 2025 was reported at $16.3 million, with a year-over-year growth of 3% [1] - SaaS Subscription revenue reached $7.8 million, reflecting a 15% year-over-year growth [1] - Annual Recurring Revenue (ARR) increased by 6% year-over-year to $44.3 million, while SaaS ARR grew by 15% to $31.4 million [7] - Bookings surged by 153% year-over-year to $23.1 million, including a significant contract valued at approximately $15 million with the Texas Office of the Attorney General [7] - Adjusted EBITDA margin was reported at 16.1%, equating to $2.62 million [7] Customer Satisfaction and Retention - The company achieved a Net Promoter Score (NPS) of 62, the highest in its history, indicating strong customer satisfaction [3] - SaaS Net Revenue Retention (NRR) stood at 108%, suggesting that existing customers are increasing their investments [3][7] Dividend Declaration - The Board of Directors declared a quarterly dividend of $0.01 per share, scheduled for payment on June 11, 2025, to shareholders of record on May 30, 2025 [3] Strategic Outlook - The company is optimistic about the ongoing acceleration of high-margin SaaS revenue and the potential for operating leverage and scalability in the future [3]

Core Viewpoint - Venus Concept Inc. reported a decline in financial performance for the first quarter of 2025, with total revenue decreasing by 22% year-over-year, attributed to challenging market conditions and timing of new system adoptions [5][10]. Financial Results Summary - Total revenue for Q1 2025 was $13.6 million, down from $17.5 million in Q1 2024, reflecting a decrease of $3.8 million or 21.9% [5][6]. - Revenue breakdown showed a 29.3% decrease in international revenue and a 16.5% decrease in U.S. revenue [6]. - Revenue from products—systems decreased by 25%, and lease systems revenue also saw a 25% decline [6][7]. - Gross profit for Q1 2025 was $8.8 million, a decrease of 25% compared to Q1 2024, with a gross margin of 64.2% [7][10]. - Operating expenses decreased by 6% year-over-year to $18.3 million, driven by reductions in general and administrative, selling and marketing, and research and development expenses [8][9]. - The company reported a GAAP net loss of $12.4 million for Q1 2025, compared to a net loss of $9.8 million in Q1 2024 [10][11]. Management Commentary - The CEO emphasized solid execution despite a challenging environment and indicated a focus on managing cash burn and making targeted investments for long-term growth [3][4]. - The company enhanced its balance sheet with a new bridge loan amendment and two equity capital transactions, indicating validation from investors regarding its potential value creation [3][4]. Cash Position and Debt - As of March 31, 2025, the company had cash and cash equivalents of $3.2 million and total debt obligations of approximately $35.5 million, a decrease from $39.7 million at the end of 2024 [11][12]. - The company is currently not providing full-year 2025 financial guidance due to ongoing evaluations of strategic alternatives and potential trade disruptions [12]. Conference Call Details - Management will host a conference call to discuss the quarterly results, providing an opportunity for questions and answers [13].

Financial Performance - Total revenue reached $1.1 billion[13] - Systemwide comparable sales grew by 11.1%[13, 17] - Adjusted EBITDA was $91.3 million with a margin of 8.5%[13, 16] - Net income was $13.9 million, or $0.07 per share[13] Digital Sales & Off-Premise Channels - Digital sales contributed 59% to total sales[13] - Off-premise channels accounted for approximately 43% of total systemwide sales[17] - Loyalty program had 18.8 million registered members[16] Divisional Performance - Brazil division systemwide comparable sales grew by 2.9%[24] - North Latin American Division (NOLAD) systemwide comparable sales decreased by 0.4%[27] - South Latin American Division (SLAD) systemwide comparable sales grew by 39.1%[33] Development & Capital Allocation - Opened 12 new restaurants, with 10 being free-standing locations[13, 75] - Capital expenditures totaled $48.8 million, including $21.4 million for growth[75]

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 10% year-over-year, reaching $104.4 million [5][13] - Gross profit for Q1 2025 was $17.2 million, representing a 44.1% increase compared to Q1 2024 [14] - Adjusted EBITDA loss was $5.1 million, an improvement from a loss of $10.9 million in Q1 2024 [15] - Net loss for the quarter was $19.6 million, an improvement of $303,000 compared to Q1 2024 [15] - Free cash flow was negative $3.9 million, compared to negative $15.4 million in Q1 2024 [16] Business Line Data and Key Metrics Changes - The Retail Pharmacy and Dispensary business generated $49.3 million in revenue, growing over 20% year-over-year [6] - Fee-for-service revenue grew by 2% year-over-year, reaching $35.6 million [13] - The dispensary segment saw a 24.2% growth, driven by increased prescription attachments to patient visits [13] Market Data and Key Metrics Changes - The company added over 80,000 lives under new capitation contracts in Q1 2025, with anticipated new contracts projected to add approximately $50 million in annualized revenue [6][19] - The company is focusing on expanding its presence in Florida, California, and Nevada markets [6] Company Strategy and Development Direction - The company aims for profitability and positive cash flow by the end of 2025, with a focus on operational management and strategic market expansion [5][22] - A new fully delegated capitation agreement in Florida is expected to enhance management capabilities and future opportunities [7] - The company is outsourcing its clinical trials program to Helios Clinical Trials to accelerate growth in existing and new markets [9] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance despite a projected $5 million reduction in revenue due to the outsourcing of clinical trials [19] - The company is closely monitoring potential impacts from tariffs and drug pricing regulations but currently does not anticipate negative effects on guidance [20][21] - Management highlighted a strong pipeline of new contracts and a commitment to maintaining SG&A expenses flat for 2025 [32] Other Important Information - The company successfully executed a partial paydown of $20 million in convertible preferred debt and raised $16 million in capital, strengthening its financial position [10] - The Chief Clinical Officer role was created to enhance the company's clinical capabilities in response to the evolving drug landscape [11] Q&A Session Summary Question: Can you talk about the gross profit growth of 44% year-over-year? - The growth was driven by a one-time rebate of $1.5 million and favorable drug pricing changes [26][28] Question: Can you discuss the fee-for-service revenue growth? - Fee-for-service revenue increased by 2% year-over-year, with a robust pipeline of new contracts expected to contribute to future growth [29][35] Question: What are the expectations for SG&A management in 2025? - The company aims to keep SG&A expenses roughly flat while seeking efficiencies through technology initiatives [32] Question: Are there any significant contract renewals coming up? - There are no significant renewals expected, as most relationships are multi-year and auto-renew [54] Question: How does the trend of delivering cancer care at home align with the company's business? - The company views this trend positively and is exploring innovative ways to deliver therapeutics in the home setting [56]